A potential therapeutic target for gastric cancerApril 17, 2009Gastric cancer (GC) is the fourth most common malignancy and the second most frequent cause of cancer-related death in the world. The carcinogenesis of GC involved numerous genetic and epigenetic alterations, as well as many environmental risk factors. Environmental pollutants such as polycyclic aromatic hydrocarbons (PAHs) and halogenated hydrocarbons (HAHs) are well-known carcinogens that play important roles in GC development. The toxic effects of PAHs and HAHs are mediated by a conserved signaling pathway that binds and activates the aryl hydrocarbon receptor (AhR). AhR is a ligand-activated transcription factor and can mediate the carcinogenic and other toxic effects of a variety of environmental pollutants. Many studies in recent years have demonstrated a close relationship between AhR and tumorigenesis. However, the role of AhR in gastric tumorigenesis is still unclear. A research team led by Dr Min-Hu Chen from China addressed this question. Their study will be published on April 14, 2009 in the World Journal of Gastroenterology. In this study, RT-PCR, real-time PCR, and Western blotting were performed to detect AhR expression in 39 GC tissues and five GC cell lines. AhR protein was detected by immunohistochemistry (IHC) in 190 samples: 30 chronic superficial gastritis (CSG), 30 chronic atrophic gastritis (CAG), 30 intestinal metaplasia (IM), 30 atypical hyperplasia (AH), and 70 GC. The AhR agonist tetrachlorodibenzo-para-dioxin (TCDD) was used to treat AGS cells. MTT assay and flow cytometric analysis were performed to measure the viability, cell cycle and apoptosis of AGS cells. They found that AhR expression was significantly increased in GC tissues and GC cell lines. IHC results indicated that the levels of AhR expression gradually increased, with the lowest levels in CSG, followed by CAG, IM, AH and GC. AhR expression and nuclear translocation were significantly higher in GC than in precancerous tissues. TCDD inhibited proliferation of AGS cells via induction of growth arrest at the G1-S phase. This is the first report suggesting an inhibitory role of AhR agonists on human GC cell growth. Furthermore, the present findings suggest that AhR may be a potential therapeutic target for GC. World Journal of Gastroenterology |
|||||||||||||||||||||
| Related Gastric Cancer Current Events and Gastric Cancer News Articles Is short-term Celecoxib intervention a effective method for preventing gastric carcinogenesis? Since the isolation and culture of Helicobacter pylori (H. pylori) in 1983, this bacterium has become accepted as an important human pathogen for the development of gastritis, peptic ulcer, and gastric cancer. A new explanation of 'Asian paradox' Although Helicobacter pylori (H. pylori) has been classified as a class I (or definite) carcinogen by World Health Organization (WHO), the controversy as to why only a minority of infected patients develop gastric cancer still remains. Will genomics help prevent the next pandemic? This week, the Public Library of Science, an open-access publisher, presents the "Genomics of Emerging Infectious Disease," a collection of essays, perspectives, and reviews that explores how genomics-with all its associated tools and techniques-can provide insights into our understanding of emerging infectious disease. Protein interaction network can respond Helicobacter pylori infection? Helicobacter pylori (H pylori) is a gram negative bacterium which infects about 50% of the world population. H pylori colonization causes a strong systemic immune response. A case of post-gastrectomy acute pancreatitis Gastrectomy is commonly performed for both benign and malignant lesions. Although the incidence of post-gastrectomy acute pancreatitis (PGAP) is low compared to other well-recognized post-operative complications, it has been reported to be associated with a high mortality rate. Does Helicobacter pylori eradication therapy prevent gastric cancer? Although it has been demonstrated that Helicobacter pylori causes gastric cancer, it is still controversial that whether H. pylori eradication therapy is effective in primary prevention of gastric cancer. New blood tests promise simple, cost-effective diagnosis of gastrointestinal cancers Promising results from two new blood tests that can aid in the early identification of patients with gastrointestinal (GI) cancers will be presented at Europe's largest cancer congress. NIH study reveals new genetic culprit in deadly skin cancer Drawing on the power of DNA sequencing, National Institutes of Health researchers have identified a new group of genetic mutations involved in the deadliest form of skin cancer, melanoma. PPAR-g agonists have potential therapeutic role in gastric carcinoma? Recently, the potential of PPAR-γ as a target for the prevention and treatment of cancer has been widely studied. D2 lymphadenectomy improves the long-term survival for patients with node-negative gastric cancer Many studies favor an extended lymphadenectomy at the time of a potentially curative gastrectomy for node-positive gastric cancer, and the risk of long-term death tends to decrease when the number of resected lymph nodes increases to about 25. More Gastric Cancer Current Events and Gastric Cancer News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||